Stefano Poletto
Overview
Explore the profile of Stefano Poletto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saporita I, Calabrese M, Poletto S, Turco F, Di Stefano R, Caffo O, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102255.
PMID: 39615118
Background: 20% of prostate cancer (PC) patients harbor germinal or somatic alterations in homologous recombination repair (HRR) genes, including BRCA1/2. BRCA mutations represent predictive biomarkers for treatment with polyadenosine diphosphate-ribose...
2.
Nepote A, Poletto S, Bertaglia V, Carnio S, Piumatti C, Lanzetta C, et al.
Crit Rev Oncol Hematol
. 2024 Nov;
205:104540.
PMID: 39486561
Single-agent osimertinib has improved outcomes in EGFR-mutated lung cancer patients with brain metastases (BMs), but still, 40 % of them will experience an intracranial progression. We performed a systematic review...
3.
Picca F, Giannotta C, Tao J, Giordanengo L, Munir H, Botta V, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39409152
Genomic-oriented oncology has improved tumor classification, treatment options, and patient outcomes. However, genetic heterogeneity, tumor cell plasticity, and the ability of cancer cells to hijack the tumor microenvironment (TME) represent...
4.
Farinea G, Calabrese M, Carfi F, Saporita I, Poletto S, Delcuratolo M, et al.
Cells
. 2024 Aug;
13(16).
PMID: 39195285
Neuroendocrine differentiation (NED) represents a possible androgen receptor pathway inhibitors (ARPI) resistance mechanism in metastatic castration resistance prostate cancer (mCRPC). As mCRPC with NED has been excluded from clinical trials...
5.
Turco F, Buttigliero C, Delcuratolo M, Gillessen S, Vogl U, Zilli T, et al.
Clin Genitourin Cancer
. 2024 Jul;
22(5):102138.
PMID: 38996529
Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted...
6.
Calabrese M, Saporita I, Turco F, Gillessen S, Castro E, Vogl U, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203248
Androgen receptor pathway inhibitors (ARPI) and polyadenosine diphosphate-ribose inhibitors (PARPi) are part of the standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC). There is biological evidence that...
7.
Poletto S, Paruzzo L, Nepote A, Caravelli D, Sangiolo D, Carnevale-Schianca F
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201531
The introduction of immunotherapy revolutionized the treatment landscape in metastatic melanoma. Despite the impressive results associated with immune checkpoint inhibitors (ICIs), only a portion of patients obtain a response to...
8.
Giraudo L, Cattaneo G, Gammaitoni L, Iaia I, Donini C, Massa A, et al.
J Exp Clin Cancer Res
. 2023 Nov;
42(1):310.
PMID: 37993874
Background: Even acknowledging the game-changing results achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion of patients (40-60%) still fail to...
9.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo A, et al.
Eur J Cancer
. 2023 Apr;
187:25-35.
PMID: 37099946
Background: Immunotherapy has improved the survival of patients with stage IV melanoma. In responders, clinical benefits may be long-lasting and persist even after treatment discontinuation. The optimal duration of anti-PD1...
10.
Turco F, Di Prima L, Pisano C, Poletto S, De Filippis M, Crespi V, et al.
Res Rep Urol
. 2023 Jan;
15:9-26.
PMID: 36698681
Prostate cancer (PC) is a hormone-sensitive tumor. Androgen deprivation therapy (ADT) is the cornerstone of systemic therapy for patients with intermediate or high-risk localized, recurrent, and metastatic prostate cancer. Although...